Haleon (LON:HLN) Third Quarter 2022 ResultsKey Financial Results
- Net income: UK£345.0m (up by UK£345.0m from 3Q 2021).
- EPS: UK£0.037.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Haleon Earnings Insights
Looking ahead, revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Personal Products industry in the United Kingdom.
The company's share price is broadly unchanged from a week ago.
Balance Sheet AnalysisWhile earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Haleon's balance sheet.
Valuation is complex, but we're helping make it simple.
Find out whether Haleon is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Adequate balance sheet and slightly overvalued.